N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

Neuroblastoma Clinical Trial

— DFMO  

Official title:

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02030964
• Other study ID #: N2012-01
• Secondary ID: P01CA081403
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: January 16, 2014
• Est. completion date: December 30, 2024

Study information

• Verified date: February 2024
• Source: New Approaches to Neuroblastoma Therapy Consortium
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will combine an oral drug called DFMO with celecoxib (also oral) and two IV chemotherapy medicines called cyclophosphamide and topotecan. - To find the highest dose of DFMO that can be given with celecoxib, cyclophosphamide and topotecan without causing severe side effects. - To find out the side effects seen by giving DFMO at different dose levels with celecoxib, cyclophosphamide and topotecan. - To measure the levels of DFMO in the blood at different dose levels. - To determine if your tumor gets smaller after treatment with DFMO, celecoxib, cyclophosphamide and topotecan. - To determine if specific gene changes in you or your tumor makes you more prone to side effects or affects your tumor's response to the combination of DFMO, celecoxib, cyclophosphamide and topotecan. - To determine if the amount of normal chemicals in your body called polyamines go down in response to DFMO, celecoxib, cyclophosphamide and topotecan, and whether you are more likely to have a good response to the treatment if they do.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 30 Years

Eligibility

Inclusion Criteria:

• Patients must be > 2 years and < 30 years of age when registered on study.
• Patients must have recurrent/progressive high-risk neuroblastoma, refractory high-risk neuroblastoma that had less than a partial response to standard treatment or persistent high-risk neuroblastoma that had at least a partial response to standard treatment.
• All patients must have at least ONE site of evaluable disease.
• Patients must have adequate heart, kidney, liver and bone marrow function.
• Patients who have bone marrow disease must still have adequate bone marrow function to enter the study.
• Patients with other ongoing serious medical issues must be approved by the study chair prior to registration.

Exclusion Criteria:

• Females of childbearing potential that do not have a negative pregnancy test.
• Patients that are pregnant, breast feeding, or unwilling to use effective contraception during the study
• Patients status post allogeneic stem cell transplant.
• Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
• Patients with disease of any major organ system that would compromise their ability to withstand therapy.
• Patients who are on hemodialysis.
• Patients with an active or uncontrolled infection. Patients on prolonged antifungal therapy are still eligible if they are culture and biopsy negative in suspected radiographic lesions and meet other organ function criteria.
• Patients with active bleeding of the GI tract or patients who have symptoms associated with stomach irritation (known as gastritis).
• Patients who have had a seizure within 12 months prior to enrollment and patients receiving anti-convulsant therapy for a seizure disorder.
• Patients with known Aspirin-Hypersensitivity triad (asthma, allergic rhinitis, ASA hypersensitivity).
• Patients with known hypersensitivity to celecoxib or other NSAIDs, aspirin or sulfonamides.

Related Conditions & MeSH terms

• Neuroblastoma

Intervention

Drug:
• DFMO

• Celecoxib

• Cyclophosphamide

• Topotecan

Locations

Country	Name	City	State
Australia	Sydney Childrens Hospital KCC	Randwick
Canada	Hospital for Sick Children	Toronto	Ontario
United States	C.S Mott Children's Hospital	Ann Arbor	Michigan
United States	AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus	Atlanta	Georgia
United States	Children Hospital of Colorado	Aurora	Colorado
United States	Childrens Hospital Boston, Dana-Farber Cancer Institute.	Boston	Massachusetts
United States	University of Chicago Comer Children's Hospital	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Cook Children's Medical Center - Fort Worth	Fort Worth	Texas
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California
United States	Children's Hospital and Regional Medical Center - Seattle	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
New Approaches to Neuroblastoma Therapy Consortium	National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events as a measure of safety and tolerability.	The standard 3+3 design for dose escalation will be utilized. 3-6 patients will enroll at each of 4 dose levels, but enrollment to a dosing cohort will cease after observation of DLTs in 2 or more patients. A minimum of 2 to a maximum of 24 patients will be enrolled assuming all 4 dose levels require 6 patients before an MTD is determined. A total of 12 patients may be enrolled at the study defined MTD (including those used to define the MTD) to provide additional adverse event data for safety evaluation.	Approximately 1 year